1. Home
  2. EDIT vs NC Comparison

EDIT vs NC Comparison

Compare EDIT & NC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDIT
  • NC
  • Stock Information
  • Founded
  • EDIT 2013
  • NC 1913
  • Country
  • EDIT United States
  • NC United States
  • Employees
  • EDIT N/A
  • NC N/A
  • Industry
  • EDIT Biotechnology: Biological Products (No Diagnostic Substances)
  • NC Coal Mining
  • Sector
  • EDIT Health Care
  • NC Energy
  • Exchange
  • EDIT Nasdaq
  • NC Nasdaq
  • Market Cap
  • EDIT 263.7M
  • NC 286.1M
  • IPO Year
  • EDIT 2016
  • NC N/A
  • Fundamental
  • Price
  • EDIT $2.57
  • NC $39.14
  • Analyst Decision
  • EDIT Buy
  • NC
  • Analyst Count
  • EDIT 12
  • NC 0
  • Target Price
  • EDIT $5.40
  • NC N/A
  • AVG Volume (30 Days)
  • EDIT 1.7M
  • NC 5.8K
  • Earning Date
  • EDIT 08-12-2025
  • NC 10-29-2025
  • Dividend Yield
  • EDIT N/A
  • NC 2.60%
  • EPS Growth
  • EDIT N/A
  • NC N/A
  • EPS
  • EDIT N/A
  • NC 4.23
  • Revenue
  • EDIT $38,901,000.00
  • NC $265,880,000.00
  • Revenue This Year
  • EDIT N/A
  • NC N/A
  • Revenue Next Year
  • EDIT N/A
  • NC N/A
  • P/E Ratio
  • EDIT N/A
  • NC $9.17
  • Revenue Growth
  • EDIT N/A
  • NC 27.25
  • 52 Week Low
  • EDIT $0.91
  • NC $25.19
  • 52 Week High
  • EDIT $4.12
  • NC $45.50
  • Technical
  • Relative Strength Index (RSI)
  • EDIT 46.57
  • NC 55.37
  • Support Level
  • EDIT $2.66
  • NC $38.48
  • Resistance Level
  • EDIT $2.78
  • NC $39.31
  • Average True Range (ATR)
  • EDIT 0.22
  • NC 1.03
  • MACD
  • EDIT -0.02
  • NC 0.35
  • Stochastic Oscillator
  • EDIT 39.39
  • NC 85.68

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

About NC NACCO Industries Inc.

NACCO Industries Inc is a holding company that operates in the mining and natural resource industries. It has three operating segments that are coal mining, North American mining (NA mining), and minerals management. The majority of its revenue is from the coal mining segment. This segment operates surface coal mines under long-term contracts with power generation companies and an activated carbon producer pursuant to a service-based business model. The NA mining segment provides value-add contract mining and services for producers. Minerals management generates income from royalty-based leases by acquiring and promoting oil, gas, and coal mineral interests. The company is diversifying beyond coal mining due to political and economic pressures associated with carbon emissions.

Share on Social Networks: